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Abstract
Background:  The autoimmune thyroid diseases (AITDs), such as Graves' disease (GD) and
Hashimoto's thyroiditis (HT), appear to develop as a result of complex interactions between
predisposing genes and environmental triggers. Susceptibility to AITDs is conferred by genes in the
human leukocyte antigen (HLA) and genes unlinked to HLA, including the CTLA-4 gene. Recently,
estrogen receptor (ER) β , located at human chromosome 14q23-24.1, was identifed. We analyzed
a dinucleotide (CA)n repeat polymorphism located in the flanking region of ERβ  gene in patients
with AITDs and in normal subjects. High heterozygosity makes this polymorphism a useful marker
in the genetic study of disorders affecting female endocrine systems. We also correlated a ERβ  gene
microsatellite polymorphism with bone mineral density (BMD) in the distal radius and biochemical
markers of bone turnover in patients with GD in remission.
Results:  Fourteen different alleles were found in 133 patients with GD, 114 patients with HT, and
179 controls subjects. The various alleles were designated as allele*1 through allele*14 according
to the number of the repeats, from 18 to 30. There was no significant difference in the distributions
of ERβ   alleles  between  patient  groups  and  controls.  Although  recent  study  demonstrated  a
significant relation between a allele*9 in the ERβ  gene and BMD in postmenopausal Japanese
women, there were no statistically significant interaction between this allele and BMD in the distal
radius, nor biochemical markers in patients with GD in remission.
Conclusions:  The present results do not support an association between the ERβ  microsatellite
m a r k e r  a n d  A I T D  i n  t h e  J a p a n e s e  p o p u l a t i o n .  W e  a l s o  s u g g e s t  t h a t  t h e  E R β   microsatellite
polymorphism has at most a minor pathogenic importance in predicting the risk of osteoporosis as
a complication of GD.
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Background
As outlined in a paper we have already published, we an-
alyzed a dinucleotide (TA)n repeat polymorphism lying
upstream of the human estrogen receptor (ER) α  gene in
patients with autoimmune thyroid diseases (AITDs) in
normal subjects [1]. Seventeen different alleles were
found in 130 patients with Graves' disease (GD), 93 pa-
tients with Hashimoto's thyroiditis (HT), and 190 con-
trol subjects [1]. There was no significant difference in
the distributions of ERα  alleles between patients and
controls [1].
The pathogenesis of AITDs involves complex interac-
tions between genetic and environmental factors [2,3].
Susceptibility to AITDs is conferred by genes in the hu-
man leukocyte antigen (HLA) [4,5,6,7,8] and genes un-
linked to HLA, including the cytotoxic T lymphocyte
antigen (CTLA)-4 gene [9]. The existence of an ERα  gene
polymorphism has been documented, and its association
to some variant ERα  genotypes found in breast cancer
[10,11], hypertension [12], osteoporosis [13,14], general-
ized osteoarthritis [15], and some autoimmune diseases
such as rheumatoid arthritis [16] has been reported.
A gene for a second type of human ER (ERβ ) was recently
identified [17]. The ERβ  is located at human chromo-
some 14q23-24.1, where the aberration of DNA copy
number in bone disorders is frequently found [18]. This
locus was close to, but distinct from, a new susceptibility
gene (GD-1) on chromosome 14q31 [19]. Recently, an as-
sociation between some ERβ  genotypes and osteoporosis
has been reported [18]. ER belongs to the nuclear hor-
mone receptor superfamily and modulates the transcrip-
tion of target genes in response to estrogen [20], a potent
immunomodulatory hormone [21]. Estrogens appear to
play a central role in the immune response and immune-
mediated diseases [21]. In view of the possible role of es-
trogens in the pathogenesis of AITDs, we analyzed a di-
nucleotide (CA)n repeat polymorphism located in the
flanking region of ERβ  gene [18] in patients with AITDs
and in normal subjects. We also studied associaitons of a
ERβ  gene microsatellite polymorphism with distal radius
bone mineral density (BMD) and biochemical markers of
bone turnover to determine how this polymorphism
might influence the development of osteoporosis as a
complication of GD.
Results and discussion
Allele frequencies of ERβ  gene microsatellite polymor-
phism in patients and controls
In general, estrogen action is thought to be mediated by
ER, a member of the nuclear receptor superfamily [20].
Recent studies have shown the presence of ERs on cells
involved in immune response, namely thymocyte, mac-
rophages and endothelial cells [21]. Particular attention
has been focused on the dose-dependent influence of es-
trogen on immune response, which appears to be related
to the clinical symptoms of autoimmunity (i.e., the ef-
fects of pregnancy or oral contraceptive pills) [21]. The
influence of estrogens on cytokine production by target
cells, through interference with their transcriptional ac-
tivity, has also been the focus of various studies [21]. The
effect of estrogens on the expression of the proto-onco-
genes and oncosuppressor genes involved in pro-
grammed cell death (apoptosis) might also be relevant to
human autoimmunity; in particular, the uncontrolled
synovial lining cell hyperplasia associated with rheuma-
toid arthritis and the prolonged T-cell survival in system-
ic lupus erythematosus may be important [21].
The ERβ  gene, isolated by Mosselman et al. [17], has 96%
conserved amino acid residues in the DNA binding do-
main and 58% conserved residues in the ligand binding
domain compared with the respective residues for ERα .
The ERβ  microsatellite polymorphism we analyzed in
the present study has been recently characterized by
Tsukamoto et al. [22]. High heterozygosity (0.93) makes
this polymorphism a useful marker in the genetic study
of disorders affecting female endocrine systems [22]. In-
deed, an association of some ERβ  genotypes with oste-
oporosis has been reported [18]. Thus, we investigated
the relation between a dinucleotide (CA)n repeat poly-
morphism lying upstream of the human ER gene and
AITDs.
Table 1: Allele frequencies of the ERβ  gene polymorphism in pa-
tients with AITDs and in control subjects
Graves' disease Hashimoto's 
thyroiditis
Controls
ERβ  polymor-
phism
n=133, (266 al-
leles)
n=114, (228 
alleles)
n=179, (358 
alleles)
allele *1 8 (3.0%) 6 (2.6%) 11 (3.1%)
allele *2 0 (0%) 2 (0.9%) 1 (0.3%)
allele *3 0 (0%) 3 (1.3%) 1 (0.3%)
allele *4 6 (2.3%) 4 (1.8%) 14 (3.9%)
allele *5 57 (21.4%) 54 (23.7%) 87 (24.3%)
allele *6 20 (7.5%) 19 (8.3%) 24 (6.7%)
allele *7 15 (5.6%) 6 (2.6%) 21 (5.9%)
allele *8 32 (12.0%) 29 (12.7%) 36 (10.1%)
allele *9 18 (6.8%) 23 (10.1%) 32 (8.9%)
allele *10 74 (27.8%) 44 (19.3%) 87 (24.3%)
allele *11 27 (10.2%) 30 (13.2%) 31 (8.7%)
allele *12 9 (3.4%) 6 (2.6%) 7 (2.0%)
allele *13 0 (0%) 1 (0.4%) 5 (1.4%)
allele *14 0 (0%) 1 (0.4%) 1 (0.3%)
The number of subjects is shown with the corresponding percentage 
in parentheses.BMC Medical Genetics (2001) 2:1 http://www.biomedcentral.com/1471-2350/2/1
Fourteen different alleles were found in 133 patients with
GD, 114 patients with HT, and 179 controls subjects. The
various alleles were designated as allele*1 through al-
lele*14 according to their sizes, which ranged from 150
bp (containing 18 CA repeats with a 114 bp segment of
amplified flanking sequences) to 176 bp (30 CA repeats).
The distribution of ERβ  alleles in the three groups is
shown in Table 1. The allelic frequencies in our control
population are in agreement with those previously pub-
lished [18]. Allele frequencies in our GD patients and our
control subjects did not differ significantly (Χ 2 = 11.71, 13
degrees of freedom, P = 0.55). Allele frequencies in our
HT patients and our control subjects also did not differ
significantly (Χ 2 = 16.05, 13 degrees of freedom, P =
0.25). According to our power calculations, we could ex-
clude both associations with relative risk > 0.5 for the
groups analyzed in Table 1 (GD patients vs. control sub-
jects) and associations with relative risk > 0.3 for the
groups analyzed in Table 1 (HT patients vs. control sub-
jects).
Associations of ERβ  gene microsatellite polymorphism 
with distal radius BMD and biochemical markers of bone 
turnover
Ogawa et al. [18] demonstrated that, when they separat-
ed postmenopausal Japanese women into two groups
bearing at least one allele*9 (26 CA repeat) and those
who did not, the former subjects had significantly higher
Z score of L2-4 BMD. Thus, Z score of distal radius BMD
and bone turnover markers in 92 female GD patients in
remission were compared between the groups (Table 2).
There was no significant difference of the Z score of distal
radius BMD and bone turnover markers between the
groups.
Conclusions
Our data did not appear to indicate any association be-
tween a dinucleotide repeat polymorphism located in the
flanking region of ERβ  gene and the AITDs analyzed.
However, this does not rule out the ERβ  gene as a whole;
other polymorphisms within the gene could still be asso-
ciated with AITD. There are also limitations in using mi-
crosatellite markers with multiple allleles in case-control
studies. Our result might be indicative of a large diversity
in the genetic backgrounds of AITDs, although this ob-
servation deserves further analysis in a larger group of
AITD patients. We also suggest that the ERβ  microsatel-
lite polymorphism has at most a minor pathogenic im-
portance in predicting the risk of osteoporosis as a
complication of GD, although further study is warranted
to confirm the affects of this polymorphism on BMD and
risk of osteoporosis.
Materials and methods
Materials and methods used in this paper follow closely
on the ones described in a paper we have already pub-
lished [1].
Subjects
One hundred and thirty-three unrelated Japanese wom-
en with GD and 114 unrelated Japanese women with HT
participated in this study. GD was diagnosed from clini-
cal symptoms and biochemical confirmation of hyper-
thyroidism, including diffuse goiter, ophthalmopathy,
elevated radioactive iodine uptake, and elevated thyroid
hormone levels. HT patients had documented clinical
and biochemical hypothyroidism requiring thyroid hor-
mone replacement therapy and showed autoantibodies
against thyroid peroxidase with or without antibodies
against thyroglobulin. Remission of GD is defined as fol-
lows: both thyrotropin receptor antibody (TRAb) and
thyroid-stimulating antibody (TSAb) in a negative range
for 6 months, and a subsequent relatively stable euthy-
roid state over at least 6 months after cessation of an-
tithyroid drug treatment. Remission ranged from 0.5 to
22.0 years. The effect of the ERβ  microsatellite polymor-
phism on BMD in the distal radius and biochemical
markers of bone turnover were investigated in the 92 GD
patients optional in remission (age range, 47 to 78 years),
none of whom had been treated with radioiodine, sur-
gery, or drugs that could affect bone turnover or BMD
prior to the study. One hundred and seventy-nine unre-
lated Japanese women without clinical evidence or fam-
ily history of any autoimmune diseases were selected as
normal control subjects. All study participants lived in
the Tokyo metropolitan area. The research protocol was
approved by the ethics committee of Showa University
hospital, and informed consent was obtained from all pa-
tients and controls.
Table 2: Comparison of background and biochemical data of GD 
patients in remission between the two groups of genotype
Genotype
Items I (-) I (+) P value
Subjects 81 11
Age 55.0 ±  11.1 59.1 ±  10.6 n.s
Radius BMD (Z-score) 0.104 ±  1.677 0.714 ±  1.313 n.s
S-bone type ALP (IU/L) 71.3 ±  45.0 74.2 ±  34.5 n.s.
S-osteocalcin (ng/mL) 6.3 ±  2.8 5.1 ±  2.3 n.s.
U-total hydroxyproline 18.6 ±  8.8 19.9 ±  5.3 n.s.
(nmol/mmol creatinine)
U-total deoxypyridinoline 5.0 ±  2.2 6.4 ±  3.4 n.s.
(nmol/mmol creatinine)
S, serum; U, urine; BMD, bone mineral density; ALP, alkaline phos-
phatase; n.s., not significant. Data are means ±  SD except where noted.BMC Medical Genetics (2001) 2:1 http://www.biomedcentral.com/1471-2350/2/1
Measurement of biochemical markers
Blood and urine samples were collected early in the
morning after an overnight fast. Both serum and urine
were stored at -70° C until assayed. Serum concentration
of bone alkaline phosphatase (B-ALP) was measured by
densitometric scanning following polyacrylamide disc
gel electrophoresis (PAGE). Osteocalcin (OC) was meas-
ured in serum with an IRMA. Materials for both assays
were obtained from Mitsubishi Kagaku BCL (Tokyo, Ja-
pan). Intra- and interassay coefficients of variation were
less than 10%. Urinary hydroxyproline (Hp) and deox-
ypyridinoline (Dpyr) were measured with high-perform-
ance liquid chromatography (HPLC; Japan
Spectroscopic, Tokyo, Japan). Intra-assay coefficients of
variation were less than 2.0% for Hp and 5.8% for Dpyr.
Interassay coefficients of variation were less than 0.2%
for Hp and 6.8% for Dpyr. Values of urinary Hp and Dpyr
were corrected for urinary creatinine concentration,
which was measured with an autoanalyzer.
Bone mineral density analysis
BMD was measured at the distal one third of the left ra-
dius with dual energy X-ray absorptiometry (DEXA;
DTX-200, Osteometer, Copenhagen, Denmark). With
this equipment, coefficients of variation in our laborato-
ry were 1.0%. BMD was expressed as a Z-score represent-
ing the number of standard deviations (SDs) by which a
value deviated from the mean BMD in 4095 healthy Jap-
anese female controls aged 20 to 90 years.
Determination of microsatellite polymorphism by 
polymerase chain reaction
Genomic DNA was isolated from whole blood with a
Genomix kit (Talent, Trieste, Italy). Microsatellite mark-
er loci were typed with fluorescence-based methods
[23,24]. Polymerase chain reaction (PCR) was per-
formed with oligonucleotide primers designed to amplify
a polymorphic (CA)n repeat in the flanking region of the
human ERβ  gene [18]. PCR was performed in a total vol-
ume of 20 µ l of the following mixture: 100 ng of human
genomic DNA, 5 pmol of each primer (Cy-5'-GGTAAAC-
CATGGTCTGTACC-3' and 5'-AACAAAATGTTGAAT-
GAGTGGG-3'), 200 µ M of each dNTPs, 2 µ l of 10 x
reaction buffer (Takara Shuzo Co., Kyoto, Japan); and 1
unit of Taq DNA polymerase (Takara Shuzo Co.). Thirty
PCR cycles of 30 sec at 94° C, 30 sec at 61° C, and 30 sec
at 72° C were performed. The amplified fragments were
analyzed by electrophoresis with an automatic DNA se-
quencer with 8% or 6% polyacrylamide gels containing 7
M Urea (Amersham Pharmacia Biotech, Buckingam-
shire, UK). The raw data were converted to dinucleotide
repeat polymorphic band patterns with the use of a soft-
ware program (Amersham Pharmacia Biotech). The
number of CA repeats in each amplified product was de-
termined by comparison with a ladder of control DNAs.
Statistical Analyses
Comparisons between the various alleles in patients with
AITDs and in controls were made with the Χ 2- test. Fish-
er's exact test was used when necessary. The relative risk
was calculated by Woolf's method [25]. Comparison of
BMD in Z scores and biochemical markers between the
group of individuals possessing one or two alleles of the
genotype and the group without that genotype were per-
formed using Student's t test. A P value less than 0.05
was considered statistically significant.
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